In pancreatic cancer models, BET inhibition reduces HO-1 expression in macrophages and suppresses tumor-promoting cytokines such as IL-6, CCL2, and GM-CSF, demonstrating a direct link between BET activity and the immunosuppressive tumor microenvironment (99). The gene discussed is CCL2; the disease is neoplasm.